Swiss biopharmaceutical company AC Immune SA (ACIU) announced Monday that it will regain all global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab. The decision follows termination of the collaboration agreements with Roche Group (RHHBY) and its unit Genentech.
The company noted that both antibodies have been evaluated in clinical studies for Alzheimer's disease or AD. AC Immune will also regain rights to existing GMP drug-product for clinical testing as well as associated data generated under each of the agreements.
AC Immune said it will carefully review and evaluate available data sets, including the final open label extension results from the Lauriet trial when they become available and are received in full by the firm, before decisions are made on potential further development and other opportunities.
Andrea Pfeifer, CEO of AC Immune SA, said, "Regaining the global rights to crenezumab, semorinemab and the intellectual property surrounding these targets may offer alternative routes to new growth opportunities, including combination therapies. We are confident that, with full ownership and the learnings from these programs, they could be enhanced using AC Immune's proprietary next generation technologies. Later this year we will present new data to illustrate the full potential of these and other monoclonal antibody assets."
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.